How to buy AstraZeneca shares

Own AstraZeneca shares in just a few minutes.

Fact checked
AstraZeneca logo

AstraZeneca PLC (AZN) is a leading drug manufacturers—general business based in the UK. AstraZeneca is listed on the London Stock Exchange (LSE) and employs 70,600 staff. All prices are listed in pence sterling.

How to buy shares in AstraZeneca

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: AZN in this case.
  5. Research AstraZeneca shares. The platform should provide the latest information available.
  6. Buy your AstraZeneca shares. It's that simple.

AstraZeneca share price

Use our graph to track the performance of AZN stocks over time.

AstraZeneca shares at a glance

Information last updated 2020-09-25.
52-week range5871p - 9393p
50-day moving average 8466.723p
200-day moving average 8217.417p
Wall St. target price78.83p
PE ratio 68.4677
Dividend yield 2.16p (2.52%)
Earnings per share (TTM) 163.7p
Promoted
eToro Free Stocks

Invest in AstraZeneca shares with 0% commission

Other fees may apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • If your trades get copied you can earn extra money
  • Create an account today in a few minutes

Share dealing platform comparison

Table: sorted by promoted deals first
Data indicated here is updated regularly
Name Product Price per trade Frequent trader rate Platform fees Brand description
Fineco
£2.95
£2.95
Zero platform fee
Fineco Bank is good for share traders and investors looking for a complete platform and wide offer. Your first 50 trades are free with Fineco, until 30/09/2020. T&Cs apply. Capital at risk.
IG
0% commission on US shares, and £3 on UK shares
From £5
£0 - £24 per quarter
IG is good for experienced traders, and offers learning resources for beginners, all with wide access to shares, ETFs and funds. Capital at risk.
Hargreaves Lansdown Fund and Share Account
£11.95
£5.95
No fees
Hargreaves Lansdown is the UK's number one platform for private investors, with the depth of features you'd expect from an established platform. Capital at risk.
eToro Free Stocks
0% commission, no markup, no ticket fee, no management fee
N/A
Withdrawal fee & GDP to USD deposit conversion
Capital at risk. 0% commission but other fees may apply.
Interactive Investor
From £7.99 on the Investor Service Plan
From £7.99 on the Investor Service Plan
No transfer fees or exit fees. £9.99 a month on the Investor Service Plan
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum deposit Maximum annual fee Price per trade Brand description
Moneyfarm stocks and shares ISA
£1500
0.75%
£0
Hargreaves Lansdown stocks and shares ISA
£100
0.45%
£11.95
Hargreaves Lansdown is the UK's biggest wealth manager. It's got everything you'll need, from beginners to experienced investors. Capital at risk.
Interactive Investor stocks and shares ISA
Any lump sum or £25 a month
£119.88
£7.99
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
Saxo Markets stocks and shares ISA
No minimum deposit requirement
0.12%
£8.00
Saxo Markets offers a wide access to a range of stocks, ETFs and funds. Capital at risk.
AJ Bell stocks and shares ISA
£500
0.25%
£9.95
AJ Bell is a good all-rounder for people who to choose between shares, funds, ISAs and pensions. Capital at risk.
Fidelity stocks and shares ISA
£1000 or a regular savings plan from £50
0.35%
£10.00
Fidelity is another good all-rounder, offering a good package at a decent price. Not suited for trading shares. Capital at risk.
Nutmeg stocks and shares ISA
£100
0.75%
£0
Nutmeg offers three types of portfolios. Choose the one that goes with your investment style. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum investment Choose from Annual fee Brand description
Moneyfarm Pension
£1,500 (initial investment)
7 funds
0.35%-0.75%
Moneyfarm has pensions that are matched against your risk appetite, goals and planned retirement date. Capital at risk.
PensionBee Pension
No minimum
7 funds
0.5% - 0.95%
Pension Bee is a newbie in the pension market. It helps consolidate your pension plans into one place. Capital at risk.
Hargreaves Lansdown Pension
£100 or £25 a month
2,500 funds
0-0.45%
Hargreaves Lansdown is the UK's biggest wealth manager. It's got three different retirement options. Capital at risk.
Interactive Investor Pension
Any lump sum or £25 a month
Over 3,000 funds
£10/month
interactive investor is a flat-fee platform, which makes it cost effective for larger portfolios. Capital at risk.
Saxo Markets Pension
Saxo Markets Pension
£10
Over 11,000 funds
No annual fee
Saxo Markets gives flexibility and control over your investment strategy. Capital at risk.
AJ Bell Pension
£1,000
Over 2,000 funds
0.05-0.25%
AJ Bell has two different pension options, a self managed pension and one that is managed for you. Capital at risk.
Moneybox Pension
£1
3 funds
0.15% - 0.45% charged monthly
Manage your money with an easy-to-use Moneybox app. Capital at risk.
loading

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Capital is at risk.

Is it a good time to buy AstraZeneca stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is AstraZeneca under- or over-valued?

Valuing AstraZeneca stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AstraZeneca's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AstraZeneca's P/E ratio

AstraZeneca's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 68x. In other words, AstraZeneca shares trade at around 68x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, AstraZeneca's P/E ratio is best considered in relation to those of others within the drug manufacturers—general industry or those of similar companies.

AstraZeneca's PEG ratio

AstraZeneca's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3507. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AstraZeneca's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider AstraZeneca's PEG ratio in relation to those of similar companies.

AstraZeneca's EBITDA

AstraZeneca's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping £6.9 billion.

The EBITDA is a measure of a AstraZeneca's overall financial performance and is widely used to measure a its profitability.

To put AstraZeneca's EBITDA into context you can compare it against that of similar companies.

AstraZeneca financials

Revenue TTM £25.7 billion
Operating margin TTM 16.94%
Gross profit TTM £19.5 billion
Return on assets TTM 4.47%
Return on equity TTM 14.24%
Profit margin 8.36%
Book value 9.327p
Market capitalisation £112.1 billion

TTM: trailing 12 months

AstraZeneca's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like AstraZeneca.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

AstraZeneca's total ESG risk score

Total ESG risk: 28.59

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and AstraZeneca's overall score of 28.59 (as at 08/01/2020) is nothing to write home about – landing it in it in the 58th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like AstraZeneca is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

To gain some more context, you can compare AstraZeneca's total ESG risk score against those of similar companies.

AstraZeneca's environmental score

Environmental score: 0.19/100

AstraZeneca's environmental score of 0.19 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that AstraZeneca is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

AstraZeneca's social score

Social score: 19.54/100

AstraZeneca's social score of 19.54 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that AstraZeneca is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

AstraZeneca's governance score

Governance score: 9.86/100

AstraZeneca's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that AstraZeneca is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

AstraZeneca's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, AstraZeneca scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that AstraZeneca hasn't always managed to keep its nose clean.

Wondering how that compares? Below are the controversy scores of similar companies.

Environmental, social, and governance (ESG) summary

AstraZeneca PLC was last rated for ESG on: 2020-08-01.

Total ESG score 28.59
Total ESG percentile 58.18
Environmental score 0.19
Environmental score percentile 3
Social score 19.54
Social score percentile 3
Governance score 9.86
Governance score percentile 3
Level of controversy 3

AstraZeneca share dividends

Dividend payout ratio: 167.85% of net profits

Recently AstraZeneca has paid out, on average, around 167.85% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.52% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AstraZeneca shareholders could enjoy a 2.52% return on their shares, in the form of dividend payments. In AstraZeneca's case, that would currently equate to about 2.16p per share.

AstraZeneca's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

The latest dividend was paid out to all shareholders who bought their shares by 13 August 2020 (the "ex-dividend date").

AstraZeneca's dividend payout ratio is perhaps best considered in relation to those of similar companies.

AstraZeneca share price volatility

Over the last 12 months, AstraZeneca's shares have ranged in value from as little as 5871p up to 9393p. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while AstraZeneca's is 0.2102. This would suggest that AstraZeneca's shares are less volatile than average (for this exchange).

To put AstraZeneca's beta into context you can compare it against those of similar companies.

AstraZeneca overview

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site